FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4380078618> ?p ?o ?g. }

• W4380078618 endingPage "841" @default.
• W4380078618 startingPage "840" @default.
• W4380078618 abstract "Introduction: Elderly patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL) represent a distinct patient population with often limited treatment options. CAR-T cell treatment can offer a curative approach to this comorbid patient population, but data directly comparing standard chemotherapy with CAR-T cell therapy are scarce. MB-CART2019.1 (Zamtocabtagene autoleucel) is a tandem CAR-T cell product targeting CD20 and CD19 and is manufactured in a 12-day process, with a vein-to-vein time of 14 days. MB-CART2019.1 was introduced in a Phase I dose finding study (NCT03870945) in mainly elderly patients with r/r B-cell lymphoma. It demonstrated encouraging safety with a low incidence of neurotoxicity and cytokine release syndrome. Five out of the 12 patients in the Phase I trial achieved a complete response which were durable at two-year follow-up. The favorable safety profile and encouraging early efficacy results provided the rationale for further investigation. Trial design and Methods: This study is a pivotal Phase II randomized, multi-center, open-label study comparing the efficacy and safety of MB-CART2019.1 to standard of care (SoC) therapy in participants with r/r diffuse large B-cell lymphoma who are not eligible for high-dose chemotherapy (HDC) and ASCT (Clinical trial information: NCT04844866). A total of 168 adult patients with r/r DLBCL will be randomized to receive MB-CART2019.1 with a dose of 2.5 × 106 CAR+ T-cells per kg body weight or SoC therapy. MB-CART2019.1 is intended to be infused as a non-cropreserved product after standard lymphodepleting chemotherapy. The comparator treatment consists of R-GemOx (rituximab, gemcitabine and oxaliplatin) or Pola-BR (polatuzumab vedotin, bendamustine and rituximab). Main criteria for inclusion are i) histologically proven DLBCL and associated subtypes, according to the WHO 2016 classification ii) patients with either refractory disease after 1st-line chemoimmunotherapy or relapsed disease within ≤12 months from the completion of 1st-line therapy, and iii) patients ineligible for ASCT due to a HCT-CT score >3 or age ≥65 years and documented organ dysfunction or age ≥70 years. The primary endpoint of the trial is progression-free survival. In addition to safety endpoints, secondary endpoints in the experimental arm include persistence of MB-CART2019.1, phenotype and immune cell compositions. In summary, this trial (DALY 2-EU) evaluates the superiority of 2nd-line CAR-T cell treatment with MB-CART2019.1 compared to SoC in an elderly high-risk population of patients with r/r DLBC. It is planned to be performed in up to 50 clinical trial sites in 12 countries in Europe. The study is actively enrolling patients since August 2021. In addition, a separate pivotal Phase II trial in the USA is currently enrolling patients with r/r DLBCL who have failed at least two lines of prior systemic therapy (NCT04792489). The study is sponsored by Miltenyi Biomedicine Keywords: cellular therapies, ongoing trials Conflicts of interests pertinent to the abstract. P. Borchmann Consultant or advisory role BMS, Novartis, Miltenyi Biomedicine P. Vandenberghe Consultant or advisory role Miltenyi Biomedicine Honoraria: BMS/Celgene, Kite, a Gilead Company, Novartis, Johnson & Johnson A. Urbano-Ispizua Consultant or advisory role Miltenyi Biomedicine C. Haiuon Consultant or advisory role Miltenyi Biomedicine Honoraria: BMS, Novartis, Amgen, Roche, Abbvie, Gilead L. Griškevicius Consultant or advisory role Miltenyi Biomedicine F. Lemonnier Consultant or advisory role Miltenyi Biomedicine G. Zadoyan Employment or leadership position: Miltenyi Biomedicine U. Bethke Employment or leadership position: Miltenyi Biotec T. Overstijns Employment or leadership position: Miltenyi Biomedicine L. Hanssens Employment or leadership position: Miltenyi Biomedicine I. Bürger Employment or leadership position: Miltenyi Biotec M. Assenmacher Employment or leadership position: Miltenyi Biotec O. Reer Employment or leadership position: Miltenyi Biotec B. Friedrichs Employment or leadership position: Miltenyi Biomedicine S. Holtkamp Employment or leadership position: Miltenyi Biomedicine U. Jäger Consultant or advisory role Miltenyi Biomedicine Honoraria: Roche, Novartis, Gilead, BMS Celgene M. J. Kersten Consultant or advisory role Miltenyi Biomedicine Honoraria: Roche, Novartis, Kite/Gilead, BMS/Celgene" @default.
• W4380078618 created "2023-06-10" @default.
• W4380078618 creator A5001653820 @default.
• W4380078618 creator A5003933175 @default.
• W4380078618 creator A5012535366 @default.
• W4380078618 creator A5014347279 @default.
• W4380078618 creator A5014565935 @default.
• W4380078618 creator A5015897808 @default.
• W4380078618 creator A5026818552 @default.
• W4380078618 creator A5034222353 @default.
• W4380078618 creator A5036293139 @default.
• W4380078618 creator A5037590260 @default.
• W4380078618 creator A5047538903 @default.
• W4380078618 creator A5054328967 @default.
• W4380078618 creator A5059828504 @default.
• W4380078618 creator A5063112287 @default.
• W4380078618 creator A5064132655 @default.
• W4380078618 creator A5070609648 @default.
• W4380078618 creator A5092127485 @default.
• W4380078618 date "2023-06-01" @default.
• W4380078618 modified "2023-10-18" @default.
• W4380078618 title "A RANDOMIZED PHASE II STUDY OF MB‐CART2019.1 COMPARED TO STANDARD OF CARE IN PATIENTS WITH RELAPSED/REFRACTORY DLBCL INELIGIBLE FOR ASCT – DALY 2‐EU TRIAL" @default.
• W4380078618 doi "https://doi.org/10.1002/hon.3166_ot20" @default.
• W4380078618 hasPublicationYear "2023" @default.
• W4380078618 type Work @default.
• W4380078618 citedByCount "0" @default.
• W4380078618 crossrefType "journal-article" @default.
• W4380078618 hasAuthorship W4380078618A5001653820 @default.
• W4380078618 hasAuthorship W4380078618A5003933175 @default.
• W4380078618 hasAuthorship W4380078618A5012535366 @default.
• W4380078618 hasAuthorship W4380078618A5014347279 @default.
• W4380078618 hasAuthorship W4380078618A5014565935 @default.
• W4380078618 hasAuthorship W4380078618A5015897808 @default.
• W4380078618 hasAuthorship W4380078618A5026818552 @default.
• W4380078618 hasAuthorship W4380078618A5034222353 @default.
• W4380078618 hasAuthorship W4380078618A5036293139 @default.
• W4380078618 hasAuthorship W4380078618A5037590260 @default.
• W4380078618 hasAuthorship W4380078618A5047538903 @default.
• W4380078618 hasAuthorship W4380078618A5054328967 @default.
• W4380078618 hasAuthorship W4380078618A5059828504 @default.
• W4380078618 hasAuthorship W4380078618A5063112287 @default.
• W4380078618 hasAuthorship W4380078618A5064132655 @default.
• W4380078618 hasAuthorship W4380078618A5070609648 @default.
• W4380078618 hasAuthorship W4380078618A5092127485 @default.
• W4380078618 hasBestOaLocation W43800786181 @default.
• W4380078618 hasConcept C121332964 @default.
• W4380078618 hasConcept C121608353 @default.
• W4380078618 hasConcept C126322002 @default.
• W4380078618 hasConcept C141071460 @default.
• W4380078618 hasConcept C142424586 @default.
• W4380078618 hasConcept C143998085 @default.
• W4380078618 hasConcept C168563851 @default.
• W4380078618 hasConcept C2777701055 @default.
• W4380078618 hasConcept C2778559949 @default.
• W4380078618 hasConcept C2779338263 @default.
• W4380078618 hasConcept C2780653079 @default.
• W4380078618 hasConcept C2780850621 @default.
• W4380078618 hasConcept C2781214270 @default.
• W4380078618 hasConcept C2908647359 @default.
• W4380078618 hasConcept C31760486 @default.
• W4380078618 hasConcept C3875195 @default.
• W4380078618 hasConcept C535046627 @default.
• W4380078618 hasConcept C71924100 @default.
• W4380078618 hasConcept C87355193 @default.
• W4380078618 hasConcept C99454951 @default.
• W4380078618 hasConceptScore W4380078618C121332964 @default.
• W4380078618 hasConceptScore W4380078618C121608353 @default.
• W4380078618 hasConceptScore W4380078618C126322002 @default.
• W4380078618 hasConceptScore W4380078618C141071460 @default.
• W4380078618 hasConceptScore W4380078618C142424586 @default.
• W4380078618 hasConceptScore W4380078618C143998085 @default.
• W4380078618 hasConceptScore W4380078618C168563851 @default.
• W4380078618 hasConceptScore W4380078618C2777701055 @default.
• W4380078618 hasConceptScore W4380078618C2778559949 @default.
• W4380078618 hasConceptScore W4380078618C2779338263 @default.
• W4380078618 hasConceptScore W4380078618C2780653079 @default.
• W4380078618 hasConceptScore W4380078618C2780850621 @default.
• W4380078618 hasConceptScore W4380078618C2781214270 @default.
• W4380078618 hasConceptScore W4380078618C2908647359 @default.
• W4380078618 hasConceptScore W4380078618C31760486 @default.
• W4380078618 hasConceptScore W4380078618C3875195 @default.
• W4380078618 hasConceptScore W4380078618C535046627 @default.
• W4380078618 hasConceptScore W4380078618C71924100 @default.
• W4380078618 hasConceptScore W4380078618C87355193 @default.
• W4380078618 hasConceptScore W4380078618C99454951 @default.
• W4380078618 hasIssue "S2" @default.
• W4380078618 hasLocation W43800786181 @default.
• W4380078618 hasOpenAccess W4380078618 @default.
• W4380078618 hasPrimaryLocation W43800786181 @default.
• W4380078618 hasRelatedWork W1968116853 @default.
• W4380078618 hasRelatedWork W2006704637 @default.
• W4380078618 hasRelatedWork W2007548746 @default.
• W4380078618 hasRelatedWork W2073532400 @default.
• W4380078618 hasRelatedWork W3166781690 @default.
• W4380078618 hasRelatedWork W3216087164 @default.
• W4380078618 hasRelatedWork W4210808715 @default.
• W4380078618 hasRelatedWork W4283391970 @default.
• W4380078618 hasRelatedWork W4313491845 @default.

• next